Showing 5661-5670 of 6035 results for "".
- Alcon to Showcase New Clinical Data, Innovative Technology at ASCRShttps://modernod.com/news/alcon-to-showcase-new-clinical-data-innovative-technology-at-ascrs/2476542/Alcon will feature new clinical data along with innovative product designs and technology for the Cataract Refractive Suite during the American Society of Cataract and Refractive Surgery (ASCRS) 2019 annual meeting, taking place May 3-7 in San Diego. The company, which recently became an independ
- New Mobile Platform Records Patient Outcomes After Cataract Surgeryhttps://modernod.com/news/new-mobile-platform-records-patient-outcomes-after-cataract-surgery/2476543/Rayner has developed RayPRO, a mobile phone and web-based app for collecting patient-reported outcomes (PROs) for 3 years after surgery. The company says this is the first time such software has been available for free to ophthalmic surgeons. It is a bespoke platform that has been specific
- The Winning Pitch Challenge Featured at ASCRShttps://modernod.com/news/the-winning-pitch-challenge-featured-at-ascrs/2476539/The Winning Pitch Challenge will feature contestants with innovative ophthalmic ideas presenting to a panel of industry leaders on Sunday, May 5 at the annual American Society of Cataract and Refractive Surgery (ASCRS) conference in San Dieg
- Atia Vision Closes $20M In Series D Financing to Fund Accommodating IOLhttps://modernod.com/news/atia-vision-closes-20m-in-series-d-financing-to-fund-accommodating-iol/2476533/Atia Vision, a Shifamed portfolio company developing a modular presbyopia-correcting accommodating IOL, announced initial closing of its committed $20 million Series D preferred stock
- Staar Surgical Announces Expanded Recommended Diopter Range for EVO Visian ICL in Germany and Japanhttps://modernod.com/news/staar-surgical-announces-expanded-recommended-diopter-range-for-evo-visian-icl-in-germany-and-japan/2476531/Staar Surgical announced that leading refractive ophthalmic societies in Germany and Japan have increased the diopter range for recommended use of phakic refractive lenses, including the EVO Visian ICL, to -3.0 diopters from -6.0 diopters. The German society, the Kommission Refraktive Chir
- Jim Wachtman Joins CorneaGen as Chief Commercial Officerhttps://modernod.com/news/jim-wachtman-joins-corneagen-as-chief-commercial-officer/2476527/CorneaGen announced that James “Jim” C. Wachtman has joined the young company as chief commercial officer. Mr. Wachtman has been a leader in the cornea community for 20 years and serves as the chair of the Refractive Surgery Council, a group of industry manufacturers and ophthalmologists focused
- Sight Sciences Announces Launches of TearCare and the Enhanced OMNI Systemhttps://modernod.com/news/sight-sciences-announces-official-launches-of-tearcare-and-the-enhanced-next-generation-omni-system/2476517/Sight Sciences announced the official commercial launch of TearCare and the introduction of an aesthetically and ergonomically enhanced OMNI Surgical System, which was initially launched in February 2018. The rollout of the new devices will include product dem
- Bausch + Lomb Announces Update From Antibiotic Resistance Monitoring in Ocular Microorganism (ARMOR) Studyhttps://modernod.com/news/bausch-lomb-announces-update-from-antibiotic-resistance-monitoring-in-ocular-microorganism-armor-study/2476512/Bausch + Lomb announced the results from nearly 10 years of the ARMOR (Antibiotic Resistance Monitoring in Ocular Microorganisms) surveillance study, presented at the ARVO meeting in Vancouver. Researchers also presented preliminary 2018 surveillance data on antibiotic resistance levels. Initiate
- Roche Further Extends Tender Offer for Spark Therapeutics as FTC Review Continueshttps://modernod.com/news/roche-further-extends-tender-offer-for-spark-therapeutics-as-ftc-review-continues/2476508/Roche said Friday that it is extending its offer period related to the proposed acquisition of Spark Therapeutics for a second time to give the US Federal Trade Commission (FTC) more time to review the deal, according to FirstWord. Roche noted that the FTC’s “review of the transaction
- ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Studyhttps://modernod.com/news/reneuron-announces-presentation-of-updated-efficacy-and-safety-data-from-retinitis-pigmentosa-study/2476502/ReNeuron Group announced updated positive preliminary results in the company’s ongoing phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2a part of the trial have demonstr